THE US Food and Drug
Administration has approved
Viibryd tablets (vilazodone
hydrochloride) for the treatment of
major depressive disorder in adults.
Available in 10, 20 and 40mg
tablets, the drug’s most common
side effects include diarrhea,
nausea, vomiting, and insomnia.
MEANWHILE the FDA has also
unveiled its 2011 plan to improve
the most common path to market
for medical devices.
Key actions featured in the plan
include streamlining the “de novo”
review process for certain innovative,
lower-risk medical devices; clarifying
when clinical data should be
submitted in a premarket submission;
and establishing a new Center
Science Council of FDA experts to
ensure timely and consistent
science-based decision making.
See www.fda.gov for details.The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jan 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jan 11
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.